From a clinical point of view, the majority of PBC patients react with the PDH-E2 component of the PDC targeted by AMA (6), and in our cohort, the second most common autoAb after anti-E2 was anti-E3BP (36%), while E1β follows as third component (34%), and the other components are detected at much lower frequency (8). This evidence concerns the gene PDC and primary biliary cholangitis.